How do biosimilars sustain value, affordability, and access to oncology care?

被引：8
|
作者：
Simoens, Steven [1 ]
机构：
[1] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, B-3000 Leuven, Belgium
来源：
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2021年 / 21卷 / 03期
关键词：
Biosimilar; oncology; value; budget impact; access; BUDGET IMPACT ANALYSIS; TRASTUZUMAB BIOSIMILARS; BREAST-CANCER; HERCEPTIN(R); SAVINGS;
D O I：
10.1080/14737167.2020.1813570
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：327 / 329
页数：3
相关论文
共 50 条
  • [1] How Biosimilars Will Impact Costs and Care in Oncology
    Lyman, Gary H.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (10) : 544 - 547
  • [2] The role of biosimilars in value-based oncology care
    Patel, Kashyap B.
    Arantes, Luiz H., Jr.
    Tang, Wing Yu
    Fung, Selwyn
    [J]. CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 4591 - 4602
  • [3] How Well Is CHIP Addressing Health Care Access and Affordability for Children?
    Clemans-Cope, Lisa
    Kenney, Genevieve
    Waidmann, Timothy
    Huntress, Michael
    Anderson, Nathaniel
    [J]. ACADEMIC PEDIATRICS, 2015, 15 (03) : S71 - S77
  • [4] How do patients value the role of the breast care nurse in the Catalan Institute of Oncology?
    Rodriguez-Ortega, A.
    Ferro, T.
    Campos, G.
    Valverde, Y.
    Borras, J. M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1127 - S1128
  • [5] Uptake of Oncology Biosimilars: Managed Care Strategies to Improve Value-Based Care Systems
    Liu, YuQian
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2022, 28 (05): : S91 - S97
  • [6] Biosimilars in Oncology: Do They Really Behave Similar?
    Agarwal, P.
    Agarwal, E.
    Agarwal, S.
    Bhargav, R.
    [J]. DRUG SAFETY, 2016, 39 (10) : 1031 - 1031
  • [7] IMPLICATIONS FOR ACCESS TO INSULIN AND BIOSIMILARS: A SURVEY ON INSULIN PRICES, AVAILABILITY AND AFFORDABILITY IN THE PHILIPPINES
    Lambojon, K.
    Saeed, A.
    Hayat, K.
    Lambojon, I. J.
    Malik, U. R.
    Fang, Y.
    [J]. VALUE IN HEALTH, 2021, 24 : S81 - S81
  • [8] How similar do 'biosimilars' need to be?
    Schellekens, H
    [J]. NATURE BIOTECHNOLOGY, 2004, 22 (11) : 1357 - 1359
  • [9] How similar do 'biosimilars' need to be?
    Huub Schellekens
    [J]. Nature Biotechnology, 2004, 22 : 1357 - 1359
  • [10] Affordability of drugs used in oncology health care
    Sleijfer, Stefan
    Verweij, Jaap
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (06) : 331 - +
12345